Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ellen Bolotin"'
Autor:
Rachel D. Torok, Jennifer S. Li, Prince J. Kannankeril, Andrew M. Atz, Raafat Bishai, Ellen Bolotin, Stefanie Breitenstein, Cathy Chen, Thomas Diacovo, Timothy Feltes, Patricia Furlong, Michael Hanna, Eric M. Graham, Daphne Hsu, D. Dunbar Ivy, Dianne Murphy, Lisa A. Kammerman, Gregory Kearns, John Lawrence, Brigitte Lebeaut, Danshi Li, Christoph Male, Brian McCrindle, Pierre Mugnier, Jane W. Newburger, Gail D. Pearson, Vasum Peiris, Lisa Percival, Miriam Pina, Ronald Portman, Robert Shaddy, Norman L. Stockbridge, Robert Temple, Kevin D. Hill
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 4 (2018)
Externí odkaz:
https://doaj.org/article/358997288c0745aea8f714749db9b506
Autor:
D. Ross Camidge, Jonathan Goldman, Athan Vasilopoulos, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine Ratajczak, Elysa Noon, Shun Lu
Publikováno v:
Cancer Research. 83:CT214-CT214
Background: Teliso-V is a first-in-class c-Met-directed antibody-drug conjugate comprising the monoclonal antibody telisotuzumab, a cleavable valine-citrulline linker, and the potent microtubule polymerization inhibitor monomethyl auristatin E. In a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf9aad972f902af371105e815f68534c
https://doi.org/10.1158/1538-7445.am2023-ct214
https://doi.org/10.1158/1538-7445.am2023-ct214
Autor:
D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Vladimirovich Moiseenko, Elena Filippova, Irfan Cicin, Penelope Ann Bradbury, Nathalie Daaboul, Pascale Tomasini, Tudor-Eliade Ciuleanu, David Planchard, Mor Moskovitz, Nicolas Girard, Janet Yikai Jin, Martin Dunbar, Ellen Bolotin, Jim Looman, Christine Ratajczak, Shun Lu
Publikováno v:
Journal of Clinical Oncology. 40:9016-9016
9016 Background: Teliso-V is an antibody-drug conjugate composed of a c-Met antibody (ABT-700) and a microtubule inhibitor (monomethyl auristatin E). The phase 2 M14-239 trial (LUMINOSITY, NCT03539536) aims to identify the c-Met OE NSCLC populations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69372596ea7a48fedcff3b0556ee2a25
https://doi.org/10.1200/jco.2022.40.16_suppl.9016
https://doi.org/10.1200/jco.2022.40.16_suppl.9016
Autor:
Mikhail V. Kopp, Aleksey Severtsev, Alberto Bessudo, Ching Hsu, Oleg Gladkov, Sandro Barni, Lothar Müller, Vladimir Ivanovich Vladimirov, Lowell L. Hart, Johanna C. Bendell, Ellen Bolotin, Brian Schwartz, Bogdan Kotiv, Reinhard von Roemeling, Cathy Eng, Robert M. Langdon
Publikováno v:
International Journal of Cancer
Cetuximab in combination with an irinotecan‐containing regimen is a standard treatment in patients with KRAS wild‐type (KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of the oral MET inhibitor tivantinib to cetuximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10014a57858bd8cf11a99efdbf4d708
https://doi.org/10.1002/ijc.30049
https://doi.org/10.1002/ijc.30049
Autor:
Prince J. Kannankeril, Robert E. Shaddy, Dianne Murphy, Rachel D. Torok, Patricia Furlong, Andrew M. Atz, D. Dunbar Ivy, Danshi Li, Gail D. Pearson, Brian W. McCrindle, Ronald J. Portman, Thomas G. Diacovo, Daphne T. Hsu, Michael G. Hanna, Miriam Pina, Brigitte Lebeaut, Lisa Percival, Cathy Chen, Christoph Male, Eric M. Graham, Lisa A. Kammerman, Kevin D. Hill, Ellen Bolotin, Raafat Bishai, Pierre Mugnier, Jane W. Newburger, Jennifer S. Li, Timothy F. Feltes, John H. Lawrence, Norman Stockbridge, Robert Temple, Vasum Peiris, Stefanie Breitenstein, Gregory L. Kearns
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Children have historically been underrepresented or, indeed, omitted entirely, in drug trials, leading to a relative dearth of evidence in support of appropriate drug treatments for many pediatric diseases.[1][1], [2][2] Recent legislative initiative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cd2ba6e4ae71988837823ea2c2a6926
https://doi.org/10.1161/jaha.117.007283
https://doi.org/10.1161/jaha.117.007283
Publikováno v:
Blood. 88:1887-1894
Bone marrow transplantation (BMT) is followed by a period of profound immune deficiency, during which new T lymphocytes are generated from either stem cells or immature thymic progenitors. Interleukin-7 (IL-7) induces proliferation and differentiatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4f2d3e753f3e38525e67ae61b51a5d
https://doi.org/10.1182/blood.v88.5.1887.bloodjournal8851887
https://doi.org/10.1182/blood.v88.5.1887.bloodjournal8851887
Autor:
Joseph, Rosenthal, Anna, Pawlowska, Ellen, Bolotin, Cheryl, Cervantes, Sean, Maroongroge, Sandra H, Thomas, Stephen J, Forman
Publikováno v:
Pediatric bloodcancer. 57(1)
Transplant-associated thrombotic microangiopathy (TMA) syndromes are reported to occur with increased frequency in transplant patients treated with siroliumus combined with a calcineurin inhibitor. We performed a retrospective study of all pediatric
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::385ec5a846bc0e81c0ecb7bab69734d5
https://pubmed.ncbi.nlm.nih.gov/21557459
https://pubmed.ncbi.nlm.nih.gov/21557459
Autor:
Ellen Bolotin, Ulrike Reiss
Publikováno v:
Pediatric clinics of North America. 49(6)
The use of high-dose chemotherapy followed by autologous HCT and the use of allogeneic HCT in children and adolescents with high-risk ALL, AML, and NBL has successfully improved outcomes. For other diseases, however, the role of HCT in treatment rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23ebbcb358b55ef4a5d3f566d0755799
https://pubmed.ncbi.nlm.nih.gov/12580373
https://pubmed.ncbi.nlm.nih.gov/12580373
Autor:
Robert M. Langdon, Lowell L. Hart, Bogdan Kotiv, Lothar Mueller, Reinhard von Roemeling, Ellen Bolotin, Sandro Barni, Cathy Eng, Brian Schwartz, Aleksey Severtsev, Oleg Gladkov, Vladimir Ivanovich Vladimirov, Ching Hsu, Johanna C. Bendell, Mikhail V. Kopp
Publikováno v:
Journal of Clinical Oncology. 31:3508-3508
3508 Background: Tivantinib (ARQ 197) selectively inhibits the MET receptor tyrosine kinase, which is implicated in tumor cell migration, invasion, and metastasis. Resistance to EGFR inhibitors has been associated with activation of alternative pathw
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a72fe11cdcf5caca6df030871a76ce29
https://doi.org/10.1200/jco.2013.31.15_suppl.3508
https://doi.org/10.1200/jco.2013.31.15_suppl.3508
Publikováno v:
Pediatric Research. 39:9-9
Bone marrow transplant (BMT) is followed by a period of profound immune deficiency, which is a major problem in clinical BMT and is likely to be important for gene therapy directed at immunologic diseases, e.g., SCID or AIDS. We have previously shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da7a28d878ecf06f3a627ff9f7f04bcc
https://doi.org/10.1203/00006450-199604001-00059
https://doi.org/10.1203/00006450-199604001-00059